Ann: Regulatory Clearance received for Phase 1 trial of IMP761, page-3

".......... IMP761, a first-in-class immunosuppressive LAG-3 agonist antibody, has the potential to address the root cause of many autoimmune diseases by specifically silencing autoimmune memory T cells that accumulate at disease sites and restoring balance to the immune system........"

I am no scientist but for quite some time have looked at this as a project targeting the front of the problem and not playing catch-up. Believe the targeted trial is only the very tip of the spear for application and IMM is out in front of the market (exclusivity) with this project.
49 volunteers to be enrolled during Q3 with first data prior end of year means they are not wasting any time.
Dont expect this announcement will receive short term commendation in the the form of SP movement from Mr Market but believe it has the potential to really move the needle down the track.